A San Francisco tower is evolving into a central hub for longevity technologies, recently hosting its inaugural longevity conference.

In addition, the upcoming International Longevity Summit in Madrid is set to enhance the city's reputation as Europe's longevity capital.

The Rejuvenation Roundup for July 2025 showcases significant advancements in rejuvenation biotechnology and related global events.

In a promising development, an FDA-approved drug combination has been reported to reverse Alzheimer's symptoms in mice, utilizing existing drug databases for innovative treatments.

Moreover, AI technology has unveiled hidden effects in a previously failed Alzheimer's trial, suggesting that patient stratification could enhance treatment outcomes.

Research has indicated that correcting sugar metabolism might combat dementia by addressing the harmful accumulation of tau protein in neurons.

Interestingly, psilocybin, a psychedelic compound, has been found to extend lifespan in mice, indicating potential longevity benefits.

A non-toxic stem cell transplantation protocol has shown promise in preventing cancer in aged mice by reducing toxicity.

Additionally, senolytic compounds have been discovered to mitigate inflammation-related cognitive decline by addressing synaptic pruning issues in the hippocampus.

Dr. David Furman has emphasized the relationship between inflammation and aging, drawing from his extensive research at Stanford and the Buck Institute.

Recent studies have questioned the universality of inflammaging, suggesting that aging responses may vary significantly between industrialized and non-industrialized societies.

Finally, the 2025 Longevity Summit in Dublin highlighted the latest research in longevity and biotechnology, underscoring the ongoing global interest in these fields.